pAMP Platform
Proprietary multi-epitope concatemeric peptide technology delivering broad immune coverage against complex pathogens.
Science
A concatemeric peptide platform for complex pathogens
The pAMP platform links many precisely defined immune targets into a single protein construct — broad coverage, straightforward manufacturing, no live virus.
pAMP Platform
Many targets, one construct
Conventional vaccines usually present the immune system with a single antigen. Complex and rapidly evolving pathogens can slip past that narrow view.
pAMP takes a different approach. Multiple carefully selected peptide epitopes — the specific fragments the immune system learns to recognize — are assembled into one repeating chain. The result is a construct that teaches both antibody and T-cell responses to recognize a pathogen from several angles at once.
Because the design is modular, epitopes can be swapped or extended as new strains emerge, without rebuilding the underlying platform.
DNA-FACE Technology
DNA Fragment Assembled Concatemer Expression, explained simply
DNA-FACE is the engineering method behind pAMP. It assembles short DNA fragments into a repeating sequence, which cells then express as a single continuous peptide chain.
STEP 01
Select the targets
Immunologically important peptide sequences are identified from the pathogen of interest — the regions most likely to drive protective immunity.
STEP 02
Assemble the DNA
Short DNA fragments encoding each target are joined into a defined, repeating order — a concatemer. The number and arrangement of units are controlled by design.
STEP 03
Express the construct
Standard recombinant expression systems produce the assembled peptide chain as a single protein product, using well-established bioprocessing methods.
STEP 04
Formulate for the field
The resulting construct is thermostable and non-replicating, enabling formulations that do not depend on continuous cold-chain infrastructure.
Platform Advantages
Designed for stockpiling, deployment, and scale
DNA-FACE Technology
Enables precise assembly of repeating bioactive peptide units, producing thermostable, non-replicating vaccine constructs.
Thermostable
Cold-chain independent formulation suitable for field deployment in resource-limited settings.
Scalable Manufacturing
Compatible with standard recombinant protein production — no live virus, no complex biologics infrastructure required.
Proven Versatility
Platform has demonstrated biological activity across multiple indications including infectious disease and wound healing applications.
Non-Replicating
No live or attenuated virus in the construct, supporting a favorable safety profile and streamlined biosafety handling.
Application
First application: Hantavirus Pulmonary Syndrome
Kinexar's pAMP-based HPS vaccine candidate is designed to elicit broad neutralizing antibody and T-cell responses against Andes virus.
| Program | Pathogen | Indication | Stage | Funding Pathway |
|---|---|---|---|---|
| KNX-001 | Andes Virus (ANDV) | Hantavirus Pulmonary Syndrome (HPS) | Preclinical | BARDA NIH |
Swipe the table horizontally to see all columns.
Interested in the platform?
We share technical detail and preclinical plans with government reviewers, scientific collaborators, and prospective partners under appropriate agreements.